Relmada Therapeutics

Yahoo Finance • 26 days ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation o... Full story

Yahoo Finance • 2 months ago

Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing

Earnings Call Insights: Relmada Therapeutics (RLMD) Q3 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He em... Full story

Yahoo Finance • 2 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two indep... Full story

Yahoo Finance • 2 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system in... Full story

Yahoo Finance • 3 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla.... Full story

Yahoo Finance • 3 months ago

Promising Penny Stocks To Watch In October 2025

As the U.S. stock market navigates the complexities of a government shutdown and fluctuating employment figures, major indices like the Dow Jones have managed to shake off early declines, reflecting resilience amid uncertainty. In such tim... Full story

Yahoo Finance • 3 months ago

Relmada regains Nasdaq compliance on minimum bid price

* Relmada Therapeutics (NASDAQ:RLMD [https://seekingalpha.com/symbol/RLMD]) on Tuesday said it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. * The company’s shares maintained a closing bid price of $1.00 o... Full story

Yahoo Finance • 4 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous... Full story

Yahoo Finance • 4 months ago

On Wednesday, there are stocks with unusual volume. Let's take a look.

Which stocks have an unusual volume on Wednesday? [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PSNYW [https://www.chartmill.com/stock/quote/PSNYW/profile] 25.04% POLESTAR AUTO CLASS C-1 ADS (NASDAQ:PSNY... Full story

Yahoo Finance • 5 months ago

Relmada outlines 2026 trial launches for NDV-01 and sepranolone as pipeline advances

Earnings Call Insights: Relmada Therapeutics, Inc. (RLMD) Q2 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted the addition of two product candidates, NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compu... Full story

Yahoo Finance • 5 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system in... Full story

Yahoo Finance • 6 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent... Full story

Yahoo Finance • 2 years ago

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Relmada Therapeutics, Inc. (NASDAQ:RLMD), it sends a favourable message to the company's shareholders... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Re... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Ch... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Seagate Technology Holdings Plc (NASDAQ: STX), Chegg, Inc. (NYSE: CHG... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm

NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), DoubleVerify Holdings, Inc.... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), Seagate Technology Holdings Plc (NASDA... Full story

Yahoo Finance • 3 years ago

RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD

NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) result... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, May 14, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Cutera, Inc. (NASDAQ: CUTR), and... Full story